Amgen melanoma drug improved survival by 21 percent in interim look

[riky]

Amgen melanoma drug improved survival by 21 percent in interim look

By Deena Beasley CHICAGO (Reuters) - Data from a pivotal trial of Amgen Inc's experimental melanoma therapy shows that it improved survival by 21 percent for patients with advanced forms of the deadly skin cancer compared with a standard white blood cell-boosting drug. Final survival results are not expected until later this year, but Wall Street has been awaiting the interim trial details to help assess the drug's commercial potential within a new market of promising melanoma treatments. ...

Source: You are not allowed to view links. Register or Login